Pliant Therapeutics (PLRX) Shares Outstanding (Weighted Average) (2019 - 2026)

Pliant Therapeutics (PLRX) has 8 years of Shares Outstanding (Weighted Average) data on file, last reported at $61.8 million in Q1 2026.

• Shares Outstanding (Weighted Average) for Q1 2026 came in at $61.8 million, up 0.95% year-over-year; the trailing twelve-month figure through Mar 2026 was $61.8 million (up 0.95% YoY), and the FY2025 annual result was $61.4 million, up 1.37% from the prior year.
• Shares Outstanding (Weighted Average) rose to $61.8 million in Q1 2026 per PLRX's latest filing, from $61.4 million in the prior quarter.
• Over five years, Shares Outstanding (Weighted Average) peaked at $61.8 million in Q1 2026 and troughed at $36.1 million in Q1 2022.
• A 5-year average of $55.5 million and a median of $60.2 million in 2024 frame the typical range for Shares Outstanding (Weighted Average).
• The sharpest annual moves came in 2023 and 2026: Shares Outstanding (Weighted Average) surged 63.71% in 2023, then gained 0.95% in 2026.
• A 5-year view of Shares Outstanding (Weighted Average) shows it stood at $42.0 million in 2022, then soared by 39.75% to $58.7 million in 2023, then advanced by 3.1% to $60.5 million in 2024, then advanced by 1.37% to $61.4 million in 2025, then advanced by 0.71% to $61.8 million in 2026.
• Business Quant data shows PLRX's Shares Outstanding (Weighted Average) at $61.8 million in Q1 2026, $61.4 million in Q4 2025, and $61.4 million in Q3 2025.